Foresite Capital (Foresite) is an American, multi-stage healthcare and life sciences investment firm headquartered in Los Angeles, and with offices in The San Francisco Bay Area and New York City.

[1][3] Foresite Capital was founded in 2011 by Jim Tananbaum.

[4][5][6] Foresite Capital raised its $100 million Fund I in 2013.

[13][14] Foresite Capital has invested in companies such as Acceleron Pharma, Aimmune, Alumis, ALX Oncology, Aerie Pharmaceuticals,[15] Ascendis, Blueprint Medicines, CG Oncology, Color Genomics, Cue Health, Cytokinetics, DNAnexus,[citation needed] Editas Medicine,[16] Eikon Therapeutics, Element Biosciences,[17] Epizyme,[1] Evonetix, Intarcia Therapeutics,[18][19] Inscripta,[20] Immunomedics,[21][22] Intellia Therapeutics,[citation needed] Juno Therapeutics,[23] Karyopharm, Keryx, Kura Oncology, Keros Therapeutics, Latigo, Maze Therapeutics, MyoKardia, MyOme, Natera,[21] Nurix, Olema Oncology, Orexigen,[24] Pacific Biosciences,[25] Peloton Therapeutics, Pharvaris, MindStrong Health, Quantum-SI, Relay Therapeutics,[26] Insitro,[27] HealthVerity, Turning Point Therapeutics, Portola Pharmaceuticals, Universal American, Xaira Therapeutics, Xencor, RayThera, and WaveTech, in addition to 10x Genomics.

[28] Foresite Capital is led by Midas List honoree Jim Tananbaum along with managing directors Vikram Bajaj,[29] Dorothy Margolskee, Michael Rome, Dennis Ryan, and Hadi Tabbaa.